MetaCap

MindWalk (HYFT) vs OS Therapies (OSTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

MindWalk (HYFT) has outperformed OS Therapies (OSTX) over the past year, losing 20.2% versus a loss of 20.6%. OS Therapies is the larger company by market cap ($75.8 million vs $67.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HYFT-19.79%OSTX-24.02%
+53%+2%-50%
Oct 8, 20251 yearOct 7, 2026
HYFT+74.42%OSTX-59.50%
+289%+101%-88%
Jul 29, 20245 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HYFT versus OSTX key metrics
MetricHYFTOSTX
Share price$1.43$1.62
Market cap$67.37M$75.82M
1-day change-4.67%+4.52%
YTD return-17.58%+15.71%
1-year return-20.21%-20.59%
5-year return-77.20%—
Forward P/E—4.67
EPS (TTM)$-0.26$-1.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.99$2.25
52-week low$0.99$1.15
Distance from 52-week high-52.17%-28.00%
Analyst consensusnonestrong_buy
Avg. price target upside+202.80%+424.69%
Average volume225.20K586.70K
Shares outstanding47.11M46.81M
Employees744
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MindWalk

HYFT stock →

MindWalk Holdings Corp. operates as a bio-native AI company.

Healthcare · Biotechnology · 74 employees

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Healthcare · Biotechnology · 4 employees

HYFT vs OSTX FAQ

Which is bigger, MindWalk or OS Therapies?

OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $67.37M for MindWalk (HYFT).

Which stock has performed better over the past year, HYFT or OSTX?

HYFT returned -20.21% over the past 12 months, compared with -20.59% for OSTX (price return, excluding dividends). Past performance does not predict future results.

Are MindWalk and OS Therapies in the same industry?

Yes. Both are classified in the Biotechnology industry within the Healthcare sector.

More comparisons